Blood test may predict immunotherapy success in liver cancer

NCT ID NCT05263830

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated Apr 30, 2026 · Updated 24 times

Summary

This study is looking at a protein called Glypican-3 (GPC-3) in the blood of people with advanced liver cancer who are receiving a combination of immunotherapy drugs (Atezolizumab and Bevacizumab). The goal is to see if levels of GPC-3, alone or with other markers, can predict how well the treatment works. About 240 adults with liver cancer will participate, and their blood will be tested before treatment, at 3 weeks, and at 3 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Service hépato-gastroentérologie, Hôpital la Pitié-Salpêtrière
RECRUITING

Paris, 75013, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEPATOCELLULAR CARCINOMA